IonGate Biosciences and LIVC Technologies Establish Technology and Marketing Co-operation
News Sep 05, 2007
IonGate Biosciences GmbH and LIVC Technologies GmbH have announced a co-operation for joint development and marketing of the LIVC Technology.
LIVC is a proprietary technology that can initiate and measure voltage activated ion channels via light induction, which works similar to a remote control.
Until now, high-throughput activation and exploration of ion channels has only been possible in low quality. The so-called LIVC Technology (Light Induced Voltage Clamp) finally allows high-throughput screening of voltage activated ion channels without any loss of time or information.
Firstly, a light activated ion channel is entered into the target cells. Secondly, this ion channel is then opened via a light impulse. The activation of the ion channel leads to depolarization in turn activates the ion channels which are the targets of exploration. With LIVC, it is possible to switch on and off voltage activated ion channels under physiological conditions. Thus, the function of these ion channels in a living organism can be imitated.
The high potential of the LIVC Technology lies in the improvement of research methods in the pharmaceutical industry, for finding new, or optimizing existing, compounds that act directly on the voltage activated ion channels. With LIVC, pharmaceutical companies will be able for the first time to get high-quality information in high-throughput information on new drug candidates and their method of action.
However, the perspectives for LIVC in pharmaceutical research far exceed the high-throughput screening of new compounds. For example, scientists could study the complex network of neurons in the brain and thus can improve the diagnosis of diseases of the central nervous system.
IonGate Biosciences and LIVC Technologies have agreed to co-operate in the area of international marketing of the LIVC Technology. Further details of the agreement will be published at a later date.
IonGate will present the new technology to an international audience during the "Screening Targets & Ion Channel Targets" conference in Boston, USA, which will be held on the 10th and 11th of September 2007.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE